• 38. Chames P, Kerfelec B, Baty D. (2010)  
  Therapeutic antibodies for the treatment of pancreatic cancer.
  ScientificWorldJournal. 2010 Jun 15;10:1107-20. 

• 37. Chames P, Baty D. (2010)  
  Antibody Engineering: Phage Display and Selections on Biotinylated Antigens.
  R. Kontermann and S. Dübel. Berlin Heidelberg, Springer 1: 151-164. (Book chapter) 

• 36. Rousserie G, Sukhanova A, Even-Desrumeaux K, Fleury F, Chames P, Baty D, Oleinikov V, Pluot M, Cohen JH, Nabiev I. (2010)  
  Semiconductor quantum dots for multiplexed bio-detection on solid-state microarrays.
  Crit Rev Oncol Hematol. 2010 Apr;74(1):1-15. 

• 35. Chames P, Baty D. (2009)  
  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
  MAbs. 2009 Nov;1(6):539-47. 

• 34. Chames P, Baty D. (2009)  
  [The future of antibody fragments, made of a single immunoglobulin domain].
  Med Sci (Paris). 2009 Dec;25(12):1159-62. 

• 33. Behar G, Chames P, Teulon I, Cornillon A, Alshoukr F, Roquet F, Pugnière M, Teillaud JL, Gruaz-Guyon A, Pèlegrin A, Baty D. (2009)  
  Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen..
  FEBS J. 2009 Jul;276(14):3881-93. 

• 32. Chames P, Van Regenmortel M, Weiss E, Baty D. (2009)  
  Therapeutic antibodies: successes, limitations and hopes for the future.
  Br J Pharmacol. 2009 May;157(2):220-33. 

• 31. Chames P, Baty D. (2009)  
  Bispecific antibodies for cancer therapy.
  Curr Opin Drug Discov Devel. 2009 Mar;12(2):276-83. 

• 30. Willemsen RA, Chames P, Schooten E, Gratama JW, Debets R . (2008)  
  Selection of Human Antibody Fragments Directed Against Tumor T-Cell Epitopes for Adoptive T-Cell Therapy.
  Cytometry A. 2008 Nov;73(11):1093-9. 

• 29. Chames P, , Baty D. (2008)  
  Ingénierie des anticorps.
  Biofutur 2008 27(288):43-47. 

• 28. Behar G, Sibéril S, Groulet A, Chames P, Pugnière M, Boix C, Sautès-Fridman C, Teillaud JL, Baty D. (2008)  
  Isolation and characterization of anti-Fc{gamma}RIII (CD16) llama single-domain antibodies that activate natural killer cells. 
  Protein Eng Des Sel. 21(1):1-10  

• 27. Smith J, Grizot S, Arnould S, Duclert A, Epinat JC, Chames P, Prieto J, Redondo P, Blanco FJ, Bravo J, Montoya G, Paques F, Duchateau P. (2006)  
  A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. 
  Nucleic Acids Res. 34(22):e149.  

• 26. Baty D, Chames P (2006)
  Approved antibodies for imaging and therapeutic: an update.
  Imm. Biol. Spe. 21(5):255-263.

• 25. Arnould S*, Chames P*, Perez C, Lacroix E, Duclert A, Epinat JC, Stricher F, Petit AS, Patin A, Guillier S, Rolland S, Prieto J, Blanco FJ, Bravo J, Montoya G, Serrano L, Duchateau P, Paques F. (2006) * contributed equally to this work
  Engineering of Large Numbers of Highly Specific Homing Endonucleases that Induce Recombination on Novel DNA Targets. 
  J Mol Biol. 355(3):443-58.  

• 24. Chames P, Epinat JC, Guillier S, Patin A, Lacroix E, Paques F. (2005)
  In vivo selection of engineered homing endonucleases using double-strand break induced homologous recombination. 
  Nucleic Acids Res. 33(20):e178.  

• 23. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL. (2005)
  T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. 
  J Immunol. 174(12):7853-8.  

• 22. Dieckmann D, Schultz ES, Ring B, Chames P, Held G, Hoogenboom HR, Schuler G. (2005)
  Optimizing the exogenous antigen loading of monocyte-derived dendritic cells. 
  Int Immunol. 17(5):621-35.  

• 21. Hulsmeyer M*, Chames P*, Hillig RC, Stanfield RL, Held G, Coulie PG, Alings C, Wille G, Saenger W, Uchanska-Ziegler B, Hoogenboom HR, Ziegler A. (2005)    * contributed equally to this work
  A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3. 
  J Biol Chem. 280(4):2972-80.  

• 20. Chames P, Hoogenboom HR. (2004)
  Technologia de presentacion de anticuerpos en la superficie de fagos (spanish). 
  Nelson Santiago Vispo Ed. Combinatoria Molecular - Elfos Scientiae (Book chapter)

• 19. Mutuberria R, Satijn S, Huijbers A, Van Der Linden E, Lichtenbeld H, Chames P, Arends JW, Hoogenboom HR. (2004)
  Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries.
  J Immunol Methods. 287(1-2):31-47.

• 18. Epinat JC, Arnould S, Chames P, Rochaix P, Desfontaines D, Puzin C, Patin A, Zanghellini A, Paques F, Lacroix E. (2003)
  A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells.
  Nucleic Acids Res. 31(11):2952-62.

• 17. Willemsen RA, Debets R, Chames P, Bolhuis RL. (2003)
  Genetic engineering of T cell specificity for immunotherapy of cancer.
  Hum Immunol. 64(1):56-68

• 16. Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR and Reiter Y. (2002)
  Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.
  Proc Natl Acad Sci U S A 99(14):9421-9426

• 15. Chames P, Hoogenboom HR. (2002)
  Antibody phage display technology.
  Biotecnologia Aplicada (19):157-163

•  14. Chames P, Willemsen RA, Rojas G, Dieckmann D, Rem L, Schuler G , Bolhuis RL and Hoogenboom HR. (2002)
  TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.
  J Immunol. 169:1110-1118

•  13. Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, Hoogenboom HR and Reiter Y. (2002)
  Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, MHC-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
  Cancer Research 62(11):3184-94

•  12. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RLH, and Chames P. (2001)
  A phage display-selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 can retarget primary human T lymphocytes.
  Gene therapy 8:1601-1608
•  11. Chames P, Hoogenboom HR, Henderikx P. (2001)
  Selections on biotinylated antigens.
  OÍBrien & Aitken eds. Antibody Phage Display: Methods and protocols (book chapter)
  Methods Mol. Biol. 178:147-157    Webpage
•  10. Chames P, Hoogenboom HR, Henderikx P. (2001)
  Selections of phage-antibodies on biotinylated antigens.
  Kontermann & Dubel eds. Antibody Engineering - Springer Lab Manual (book chapter) Webpage

•  9. Willemsen RA, Weijtens MEM, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RLH. (2000)
  Grafting primary human T lymphocytes with cancer specific chimeric single chain and two chain TCR.
  Gene therapy 7(16):1369-1377

•  8. Chames P, Baty D. (2000)
  Antibody engineering and its applications in tumor targeting and intracellular immunization. (review)
  FEMS Microbiol. Lett.189(1):1-8

•  7. Hoogenboom HR and Chames P. (2000)
  Natural and designer binding sites made by phage display technology. (review)
  Immunol. Today. 21(8):371-378

•  6. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. (2000)
  Direct selection of a human antibody fragment against the tumor T-cell epitope HLA-A1/MAGE-A1 from a non-immunized phage-Fab library.
  Proc Natl Acad Sci U S A 97(14):7969-7974

•  5. Chames P, Coulon S, Baty D. (1998)
  Improving the affinity and the fine specificity of an anti-cortisol antibody by parsimonious mutagenesis and phage display.
  J Immunol. 161(10):5421-5429

•  4. Chames P, Baty D. (1998)
  Engineering of an anti-steroid antibody: amino acid substitutions change antibody fine specificity from cortisol to estradiol.
  Clin Chem Lab Med. 36(6):355-359

•  3. Chames P, Fieschi J, Baty D, Duche D. (1998)
  Intracellular immunization of prokaryotic cells against a bacteriotoxin.
  J Bacteriol. 180(3):514-518

•  2. Chames P, Fieschi J, Baty D. (1997)
  Production of a soluble and active MBP-scFv fusion: favorable effect of the leaky tolR strain.
  FEBS Lett. 405(2):224-228

•  1. Fieschi J, Niccoli P, Camilla C, Chames P, Chartier M, Baty D. (1996)
  Polymerase chain reaction-based site-directed mutagenesis using magnetic beads.
  Anal Biochem. 234(2):210-214

 

Home             C.V.           Work        Publications        Patents        Pictures

.